Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11594623 | 0.81 | LMNA (0.41) | LTA4HCYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL499914 | 0.79 | HRH3 (0.55) | LTA4HHRH3TERTLMNA | |
| SCHEMBL24795889 | 0.78 | OPRD1 (0.48) | CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28570207 | 0.77 | L3MBTL1 (0.47) | LTA4HCYP1A2SMN1; SMN2HRH3TERT | |
| SCHEMBL500612 | 0.77 | LTA4H (0.43) | LTA4HCYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL9181496 | 0.77 | TERT (0.51) | LTA4HTERT | |
| SCHEMBL4034937 | 0.75 | AGL (0.36) | TERT | |
| Succinic Acid SCHEMBL28602780 | 0.74 | ALDH1A1 (0.40) | CYP1A2MAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL29952365 | 0.74 | ACE (0.40) | LTA4HHRH3OGFRL1 | |
| SCHEMBL29952267 | 0.74 | ACE (0.40) | LTA4HHRH3OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102319184-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| CN-102319184-A | Parakeratosis inhibitor, pore contracting agent and composition for external application | SHISEIDO CO LTD | 2012-01-18 | — | — | CN | disclosed |
| CN-101175470-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2011-09-14 | — | — | CN | disclosed |
| CN-101267803-B | Wrinkle-improving agent | SHISEIDO CO LTD | 2011-06-08 | — | — | CN | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| CN-101267803-A | Wrinkle-improving agent | SHISEIDO CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| CN-101175470-A | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | LTA4H 221/4885CYP1A2 3833/4885MAPK1 2330/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | LTA4H 862/4885CYP1A2 3980/4885MAPK1 2393/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | LTA4H 304/4885CYP1A2 3658/4885MAPK1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.